Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Curcumin for the clinical treatment of rheumatoid arthritis: a systematic review and meta-analysis of placebo-controlled randomized clinical trials.

  • 2026-01-12
  • Frontiers in immunology 16
    • Yihua Fan
    • Zhiqiang Yi
    • Shijie Mao
    • Jialu Wen
    • Jiwei Zhang
    • Qiang Zhang
    • Ruihan Liu

Study Design

Type
Meta-Analysis
Sample size
n = 244
Population
244 participants with rheumatoid arthritis
Methods
Meta-analysis; searched PubMed, Embase, the Cochrane Library and Web of Science; Cochrane risk of bias tool; GRADE framework; Review Manager 5.3

Background

The efficacy and safety of curcumin in the treatment of rheumatoid arthritis (RA) remain controversial. We therefore conducted a meta-analysis to evaluate the efficacy and safety of curcumin in RA.

Methods

We searched PubMed, Embase, the Cochrane Library and Web of Science for relevant literature published up to July 30, 2025. The Cochrane risk of bias tool was used to assess bias in the included trials, and the Grade of Recommendations Assessment, Development and Evaluation (GRADE) framework was applied to evaluate the certainty of evidence. Meta-analyses were performed using Review Manager 5.3.

Results

Six studies involving 244 participants were included. The meta-analysis showed that curcumin significantly improved the following outcomes: American College of Rheumatology (ACR) 20 response (SMD = 4.35, 95%CI(2.22, 6.47), P < 0.0001; evidence certainty: very low), disease activity score(DAS-28) (SMD = -3.40, 95%CI(-5.29, -1.50), P = 0.0004; very low), erythrocyte sedimentation rate (ESR) level (SMD = -3.72, 95%CI(-5.26, -2.18), P < 0.00001; very low), C-reactive protein (CRP) level (SMD = -2.91, 95%CI(-4.42, -1.39), P = 0.0002; very low), visual analogue scale (VAS) score (SMD = -5.65, 95%CI(-6.95, -4.34), P < 0.00001; very low), tender joint count (TJC) (SMD = -2.84, 95%CI(-4.47, -1.22), P = 0.0006; very low), swollen joint count (SJC) (SMD = -4.11, 95%CI(-6.19, -2.03), P = 0.0001; very low), and rheumatoid factor (RF) level (SMD = -3.82, 95%CI(-4.62, -3.02), P < 0.00001; low).

Conclusion

Current evidence suggests that curcumin has a significant therapeutic effect on RA. However, given the limitations of this meta-analysis, future multicenter, large-sample, placebo-controlled randomized trials are warranted to further verify its efficacy and safety.

Systematic review registration

https://www.crd.york.ac.uk/PROSPERO/view/CRD420251147977, identifier CRD420251147977.

Research Insights

Back to top